QuantiaMD, the largest online physician community, and The International CardiOncology Society (ICOS) announced at the ICOS 6th annual meeting in Milan, Italy a partnership to launch the ICOS global physicians collaboration forum on QuantiaMD. This first-of-its-kind partnership brings together an emerging area of medicine with QuantiaMD’s dynamic clinical exchange to rapidly drive awareness, education and training around the cardiac implications of oncology treatments.
The Transcatheter Cardiovascular Therapeutics (TCT) conference showcases key advancements being made in interventional cardiology, focusing this year on the next generation of drug-eluting stents, bioresorbable stents, patent foramen ovale (PFO) therapy, transcatheter valve therapy and cardiac imaging technologies.
Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced six-month clinical, IVUS (Intravascular Ultrasound), OCT (Optical Coherence Tomography) and angiographic data for its 15-patient First-In-Man clinical study of the fully bioresorbable drug-eluting scaffold, the DESolve Bioresorbable Coronary Scaffold System at a late-breaking trial session of EuroPCR in Paris.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
October 19, 2012 — Volcano Corp. announced it has received both U.S. Food and Drug Administration (FDA) clearance and CE mark to market its new Visions PV .035 digital IVUS catheter in both the United States and Europe.
October 19, 2012 — Boston Scientific Corp. entered into a definitive agreement to acquire privately-held Rhythmia Medical Inc., a developer of next-generation mapping and navigation solutions for use in cardiac catheter ablations and other electrophysiology (EP) procedures.
Edwards Lifesciences announced today it received approval from the United States Food and Drug Administration (FDA) to treat high-risk aortic stenosis patients with the Edwards Sapien transcatheter aortic heart valve delivered both transfemorally and transapically (through the ribs). With the addition of high-risk patients to those eligible for the transcatheter procedure and with the approval of the transapical approach, a considerably broader group can now be treated with the Sapien valve.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
Infraredx Inc., a medical device company, and Royal Philips Electronics announced they have signed a joint development and collaboration agreement that is focused on integrating Infraredx’s true vessel characterization (TVC) Imaging System with Philips’ Allura Xpercatheterization (cath) lab imaging systems. This collaboration is intended to enable seamless access to the TVC Imaging System with Philips’ Allura X-ray systems.
October 18, 2012 — Claron Technology has introduced Withinsight Framework (WIF) version 2.1, which adds advanced new segmentation tools, registration enhancements and performance improvements to the company’s innovative platform.
AngioDynamics said it entered into a definitive agreement to acquire all the outstanding capital stock of Vortex Medical Inc., a privately held company focused on the development of innovative medical devices for the removal of thrombus, or blood clots, from occluded blood vessels.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
October 16, 2012 — Proteon Therapeutics Inc. has initiated enrollment in a Phase 1 clinical study of its lead product, PRT-201, in patients with symptomatic peripheral artery disease (PAD) of the superficial femoral or popliteal artery.
October 16, 2012 — The American Institute of Ultrasound in Medicine (AIUM) will host an Ultrasound First Forum on Nov. 12, 2012, in New York City. The forum will address the expanding role of ultrasound imaging as a “first” imaging examination and will be devoted to encouraging the use of ultrasound as a safe, effective and affordable alternative to other diagnostic imaging modalities.
October 15, 2012 — Cardiac Science has unveiled its Burdick 4250 Holter recorder — a wearable heart monitor half the size and weight of its Holter monitoring system predecessor.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Three-year data from the Zilver PTX randomized controlled trial of paclitaxel-eluting stents for femoropopliteal disease from Cook Medical demonstrate 70.7 percent primary patency in the superficial femoral artery (SFA) at 36 months for patients treated with the paclitaxel-eluting stent.
Surefire Medical Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its line of Surefire angiographic catheters. Surefire Medical will launch these products in the United States later this year.
October 12, 2012 — Biotronik announced the start of the prospective multicenter PARCADIA study. The study aims to identify risk factors that can help predict appropriate ICD interventions in patients with ischemic cardiomyopathy who have received an ICD for primary prevention according to the current ESC (European Society of Cardiology) guidelines.